TITLE

life sciences In Brief

PUB. DATE
March 2005
SOURCE
Chemical Market Reporter;3/21/2005, Vol. 267 Issue 12, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article presents information on recent developments related to life sciences. Astralis Ltd. says that preliminary results from a Phase II study of its product candidate, a novel immuno-stimulatory product for psoriasis, did not meet its primary endpoint. Generex Biotechnology Corp. reports that its product Oral-Iyn successfully replaced rapid-acting insulin in type I diabetes patients in a recently completed Phase IIb clinical study. Oral-Iyn is an oral-spray delivery system incorporating insulin.
ACCESSION #
16505647

 

Related Articles

  • GENEREX ORAL INSULIN SPRAY APPROVED BY LEBANESE GOVERNMENT.  // Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p1 

    The article reports that Lebanon's Ministry of Public Health has given its approval for Generex Biotechnology Corporation's Generex Oral-lyn proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon. The oral insulin spray...

  • First in Bananas and Noninjectable Insulin. Trecroci, D. // Diabetes Health;Jul2005, Vol. 14 Issue 7, p16 

    Reports on the approval of noninjectable insulin formulation from Generex Biotechnology in Ecuador. Estimated number of people with diabetes in the country; Implication of the decision according to the company.

  • Generex wins approval for impaired glucose tolerance study.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p13 

    The article reports that the ethics committee of the University Campus Bio-Medico of Rome has approved Generex Biotechnology Corp. to conduct a trial for its oral insulin spray Generex Oral-lyn in Italy. The trial aims to determine whether Generex Oral-lyn reduces the glucose levels of patients...

  • Rapid- and slow-acting insulins help control diabetes. Zablocki, Elaine // Managed Healthcare Executive;Jan2006, Vol. 16 Issue 1, p46 

    The article enlightens about the availability of two rapid-acting insulins with a more rapid onset and shorter duration of action than regular insulin to contain blood sugar levels in people with diabetes, whose population is increasing at an alarming rate in the United States. Byetta is a new...

  • GENEREX GETS APPROVAL FOR ORAL-LYN PHASE III TRIAL.  // Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p4 

    The article reports on the approval given by Ukraine's Ministry of Health to Generex Biotechnology Corporation for the conduct of a Phase III clinical trial for Generex Oral-lynâ„¢ at several clinical sites in the country. Generex has plans to conduct trials in seven countries. Type-1...

  • Financings Roundup.  // BioWorld Today;5/21/2009, Vol. 20 Issue 97, p10 

    The article reports on the consummation by Generex Biotechnology Corp. of a $5 million registered direct offering of the company's common stock to selected accredited investors. The offering of the company's common stock is said to have been at discount, had no warrant coverage and covers about...

  • Generex Raising $20.7M Privately For Oral-lyn Insulin Spray Trials. Boggs, Jennifer // BioWorld Today;4/3/2008, Vol. 19 Issue 65, p3 

    This article reports on the money being raised by Generex Biotechnology Corp. to support the late-stage trials of Oral-lyn, an insulin spray product for Type I and Type II diabetes patients. Eight percent of convertible notes and warrants will be issued by Generex Biotechnology to existing...

  • PRODUCTS & SERVICES.  // Endocrine Today;5/10/2008, Vol. 6 Issue 8, p34 

    This section offers news briefs on endocrine-related products and services. BioSignia has been appointed as a data-submission pathway for Bridges to Excellence, a program to promote care quality within physician practices. An oral-lyn insulin will be launched by Generex through presentations to...

  • CLINIC ROUNDUP.  // BioWorld Today;5/11/2010, Vol. 21 Issue 90, p2 

    This section offers news briefs on clinical trials including the completion by Generex Biotechnology Corp. of enrollment of patients in its Phase III trial of Generex Oral-lyn and the encouraging pharmacokinetic results obtained by QRxPharma Inc. from its trial of a controlled-release dual-opioid.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics